Rosuvastatin Calcium

DRUG16 trials

Sponsors

Centre Hospitalier Regional Et Universitaire De Brest, Ostfold Hospital Trust, Ottawa Hospital Research Institute, AstraZeneca, Abbott, Dr. B. Catharine. Craven, Ottawa Hospital Research Institute

Conditions

Acute Coronary SyndromesAdvanced Solid TumorBlood ClotCYP2C19 PoorCoronary ArteriosclerosisCoronary Heart DiseaseDeep Vein ThrombosisDrug-drug Interaction,SHR3680

Phase 1

Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin

CompletedNCT00766025

AstraZenecaCYP2C19 Poor, Extensive Metabolizers

Start: 2008-09-30End: 2009-02-28Target: 50Updated: 2009-03-02

Drug-durg Interaction of SHR3680 With Digoxin, Rosuvastatin Calcium and Metformin Hydrochloride

Jiangsu HengRui Medicine Co., Ltd.Drug-drug Interaction,SHR3680

Start: 2020-11-19End: 2021-07-05Target: 18Updated: 2020-11-09

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

WithdrawnNCT05828303

Turning Point Therapeutics, Inc.Advanced Solid Tumor, Metastatic Solid Tumor

Start: 2024-11-15End: 2025-11-30Updated: 2025-04-01

A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin

CompletedNCT06081166

NewAmsterdam PharmaHealthy Volunteers

Start: 2023-11-11End: 2024-01-22Updated: 2025-05-22

Phase 2

Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk

Dr. B. Catharine. CravenMetabolic Syndrome, Osteoporosis, Spinal Cord Injuries

Start: 2018-02-26End: 2022-12-31Updated: 2021-10-20

Phase 3

LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes

CompletedNCT00214630

AstraZenecaAcute Coronary Syndromes

Start: 2003-12-31End: 2007-08-31Updated: 2010-11-19

A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)

CompletedNCT00225589

AstraZenecaHypercholesteremia

Start: 2002-08-31End: 2006-05-31Target: 840Updated: 2010-11-19

A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)

CompletedNCT00240318

AstraZenecaCoronary Arteriosclerosis

Start: 2002-11-30End: 2005-11-30Target: 450Updated: 2010-11-19

Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood

CompletedNCT00300482

AbbottCoronary Heart Disease, Dyslipidemia, Mixed Dyslipidemia

Start: 2006-03-31Updated: 2009-06-10

A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia

CompletedNCT00463606

AstraZenecaDyslipidemia, Hypercholesterolemia

Start: 2007-04-30End: 2008-02-29Updated: 2012-10-03

A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia

CompletedNCT00491530

AbbottMixed Dyslipidemia

Start: 2007-06-30End: 2008-11-30Updated: 2012-01-20

An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia

CompletedNCT01078675

AstraZenecaFamilial Hypercholesterolaemia

Start: 2010-02-28End: 2013-02-28Updated: 2015-04-07

Statins for Venous Event Reduction in Patients With Venous Thromboembolism

RecruitingNCT04319627

Ottawa Hospital Research InstituteBlood Clot, Post Thrombotic Syndrome, Venous Thromboembolism

Start: 2021-02-10End: 2028-04-30Target: 2700Updated: 2026-01-15

Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia

EMSDyslipidemia, Type 2 Diabetes Mellitus

Start: 2023-03-31End: 2025-08-31Target: 240Updated: 2022-08-05

Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

RecruitingNCT04602754

EMSDyslipidemia Associated With Type II Diabetes Mellitus

Start: 2023-12-01End: 2027-09-30Target: 228Updated: 2025-12-08

StAtins for Venous Event Reduction in Patients with Venous Thromboembolism : The SAVER Trial

RecruitingCTIS2023-504486-23-00

Centre Hospitalier Regional Et Universitaire De Brest, Ostfold Hospital Trust, Ottawa Hospital Research InstituteDeep Vein Thrombosis, Pulmonary Embolism, Venous thromboembolism

Start: 2024-05-29Target: 750Updated: 2025-10-10

Related Papers

A Drug–Drug Interaction Study Evaluating the Pharmacokinetic Consequences of Obicetrapib Therapy on Atorvastatin or Rosuvastatin Levels in Healthy Volunteers

American Journal of Cardiovascular Drugs2025-06-262 citations

Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis—design, rationale, and methodology of the METEOR-China study

Trials2020-11-112 citations

Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia

Circulation2017-06-0898 citations

Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia.

2015-09-215 citations

One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.

2012-04-015 citations

Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.

2010-01-0122 citations